Want to join the conversation?
$ABBV said Humira delivered global operational growth of more than 17% in 2Q16. In rheumatology, Humira is the number one prescribed biologic and the company continues to grow its share position in the face of new competition. In dermatology and gastro, Humira holds a strong market leadership position, demonstrating double-digit growth YoverY.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!